Introduction
============

In the past two decades, mRNA has gained growing attention in medical research, in particular as a vehicle to deliver tumor antigens as well as activation stimuli for the induction of immune responses against cancer.[@R1]^-^[@R8]

The growing interest in mRNA as an active pharmaceutical ingredient in anti-cancer immunotherapy can be explained by its versatility and the many advantages it offers. When compared with viral vectors or plasmid DNA, mRNA is safe, as it lacks genomic integration capacity and only results in transient expression of the encoded protein. Moreover, virtually any cell type can be modified with mRNA, including hard-to-modify cells, such as dendritic cells (DCs).[@R9] The latter are critical in the priming of effective immune responses.[@R10] Therefore, it is not surprising that mRNA has been extensively exploited to deliver tumor antigens to these professional antigen-presenting cells (APCs).[@R11]^-^[@R17] The use of mRNA to deliver tumor antigens offers a number of advantages. First, mRNA is characterized by a certain degree of flexibility in the sense that all proteins of interest can be generated and that enhanced protein expression hence presentation of antigenic peptides can be obtained by structural modification of the mRNA molecule.[@R6]^,^[@R18]^,^[@R19] Second, mRNA encodes the entire tumor antigen thus enabling presentation of all epitopes contained within the encoded protein in the context of MHC class I molecules to CD8^+^ T cells.[@R20]^,^[@R21] In addition, presentation of antigenic epitopes in the context of MHC class II molecules to CD4^+^ T cells can be achieved by fusion of the tumor antigen encoding sequence to class II targeting signals.[@R22]^,^[@R23] The latter is important, since a potent anti-tumor immune response requires activation of CD4^+^ T helper 1 (T~H~1) cells and CD8^+^ cytotoxic T lymphocytes (CTLs). Finally, mRNA can be easily produced at high quantity and purity without the use of problematic materials such as animal-derived proteins, resulting in batch-to-batch reproducibility and the ability to scale up the production to meet world-wide demand.[@R1]^,^[@R3] The first description of an mRNA-based vaccination strategy was published already in the early nineties[@R24] at approximately the same time as DNA-based vaccination.[@R25] Although vaccination with mRNA resulted in the induction of adaptive B and T cell-mediated immune responses, DNA-based vaccines dominated the following ten years. Today, several strategies have been developed to deliver mRNA to DCs. These include methods to transfect DCs in vitro, including passive pulsing,[@R11]^,^[@R26]^-^[@R28] lipofection,[@R29] electroporation[@R12]^,^[@R13] and sonoporation[@R30] to name a few. As in vivo modification of APCs has gained interest over the years, it was also explored whether mRNA can be used for this purpose. The use of ex vivo mRNA-modified DCs and "naked mRNA" for cancer immunotherapy will be discussed in this review.

Immunization with Ex Vivo mRNA-Modified Dendritic Cells
=======================================================

Currently, the transfer of ex vivo mRNA-modified DCs is the method of choice for vaccination. In 1997, the FDA approved the first clinical trial based on the use of ex vivo mRNA-transfected DCs to induce an immune response in cancer patients.[@R26]^,^[@R31] Over the past decades, vaccines consisting of autologous DCs loaded with tumor antigen mRNA have proven to be safe, well tolerated and capable of inducing tumor antigen-specific immune responses in a substantial number of vaccinated patients.[@R20]^,^[@R21]^,^[@R32]^,^[@R33] Thus far several clinical trials using ex vivo mRNA-modified DCs have been conducted in different types of cancers ([Table 1](#T1){ref-type="table"}). Although objective tumor regression was not always observed, these clinical trials demonstrated the potential of mRNA-modified DCs for anti-cancer vaccination. To further optimize this approach several parameters can be scrutinized, including the exploited DC subtype and DC maturation stimulus as well as route, dose and frequency of vaccine administration.[@R34]^,^[@R35]

###### **Table 1.** Published clinical trials using ex vivo mRNA-modified DCs

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                      Year   Type of cancer                                                   Administration route   Antigen mRNA                                                    DC maturation and/or\                                     Immunological response                                                                                      Clinical response
                                                                                                                                                                                             additional therapy                                                                                                                                                    
  --------------------------- ------ ---------------------------------------------------------------- ---------------------- --------------------------------------------------------------- --------------------------------------------------------- ----------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------
  Rains et al.[@R48]          2001   colorectal cancer                                                i.v.                   total tumor mRNA                                                inclusion of keyhole limpet hemocyanin (KLH)              induction of DTH reaction (11/13)                                                                           no clinical response

  Heiser et al.[@R26]         2002   metastatic prostate cancer                                       i.v./i.d.              PSA mRNA                                                                                                                  detection of PSA-specific T cell responses                                                                  decreased serum PSA levels (6/7) and undetectable circulating tumor cells (3/7)

  Su et al.[@R27]             2003   renal cell carcinoma                                             i.v./i.d.              total tumor mRNA                                                                                                          induction of tumor antigen-specific T cell responses                                                        8/10 patient received additional therapy, 7/15 SD

  Morse et al.[@R31]          2003   metastatic CEA expressing cancers (lung, breast, colon cancer)   i.v./i.d.              CEA mRNA                                                                                                                  induction of tumor-specific T cell responses                                                                1/24 CR, 2/24 PR, 3/24 SD, 18/24 PD

  Caruso et al.[@R49]         2004   brain cancer                                                     i.d./i.v.              total tumor mRNA                                                                                                          induction of tumor-specific immune responses                                                                4/7 SD, 1/7 PR, 2/7 PD

  Caruso et al.[@R50]         2005   neuroblastoma                                                    i.v./i.d.              total tumor mRNA                                                                                                          increased proliferation of tumor-specific T cells and induction of tumor-specific humoral response          1/11 SD, 10/11 no clinical response

  Su et al.[@R51]             2005   prostate cancer                                                  i.d.                   mRNA encoding hTERT linked to LAMP1                             IL-6, IL-1β, TNF-α, PGE~2~\                               induction of CD4/CD8\                                                                                       no clinical response, reduction in circulating tumor cells
                                                                                                                                                                                             (20 h)                                                    T cell responses                                                                                            

  Dannull et al.[@R52]        2005   renal cell carcinoma/\                                           i.d.                   total tumor mRNA                                                regulatory T cell depletion\                              increase in tumor-specific T cell frequencies                                                               8/11 PD
                                     ovarian cancer                                                                                                                                          IL-6, IL-1β, TNF-α, PGE~2~\                                                                                                                                           
                                                                                                                                                                                             (20 h)                                                                                                                                                                

  Mu et al.[@R53]             2005   androgen-resistant prostate cancer                               i.d./i.n.              total mRNA of 3 allogeneic tumor cell lines                     IL-6, IL-1β, TNF-α, PGE~2~\                               DTH reaction,\                                                                                              i.d.: 3/9 PD, 6/9 SD\
                                                                                                                                                                                             (48 h)                                                    anti-vaccine specific response                                                                              i.n.: 5/10 PD, 5/10 SD

  Kyte et al.[@R54]           2006   metastatic melanoma                                              i.d./i.n.              total tumor mRNA                                                IL-6, IL-1β, TNF-α, PGE~2~\                               measurable T cell response in a number of patients                                                          i.d.: 1/8 SD, 7/8 PD\
                                                                                                                                                                                             (48 h)                                                                                                                                                                i.n.: 1/12 SD, 11/12 PD

  Kyte et al.[@R55]           2007   metastatic melanoma                                              i.d.                   total tumor mRNA                                                IL-6, IL-1β, TNF-α, PGE~2~\                               CD4/CD8 T cell responses against multiple antigens                                                          2/2 PD
                                                                                                                                                                                             (48 h)                                                                                                                                                                

  Van Tendeloo et al.[@R33]   2010   acute myeloid leukemia                                           i.d.                   WT-1 mRNA                                                       PGE~2~, TNF-α, KLH                                        CD8 T cell responses against multiple epitopes of WT-1                                                      3/10 CR

  Wilgenhof et al.[@R56]      2011   advanced melanoma                                                i.d.                   4 TAAs: Mage-A3, Mage-C2, Tyrosinase, gp100 linked to DC-LAMP   TriMix mRNA,\                                             induction of vaccinal antigen-specific CD8 T cells in 12/21 patients                                        1/17 PR, 5/17 SD
                                                                                                                                                                                             combination with IFNα-2b                                                                                                                                              

  Van Nuffel et al.[@R57]     2011   advanced melanoma                                                i.d./i.v.              4 TAAs: Mage-A3, Mage-C2, Tyrosinase, gp100 linked to DC-LAMP   TriMix mRNA                                               enhanced CD4/CD8 T cell responses                                                                           1/1 PR

  Aarntzen et al.[@R58]       2012   Advanced melanoma                                                i.n.                   mRNA encoding gp100 and tyrosinase                              KLH + matured by autologous MCM, PGE2, recombinant TNFα   Induction of TAA-specific CD4^+^ and CD8^+^ T cell responses in SKILs able to recognize multiple epitopes   stage III: 1/26 PD, 12/26 ongoing remission\
                                                                                                                                                                                                                                                                                                                                                                   stage IV: 5/19 SD, 1/19 PR, 1/19 mixed response
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: i.d., intradermal; i.n., intranodal; i.v., intravenous; KLH, keyhole limpet hemocyanin; DTH, delayed type hypersensitivity; hTERT, human telomerase reverse transcriptase; PSA, prostate specific antigen; CEA, carcinoembryonic antigen; SD, stable disease; CR, complete response; PD, progressive disease; LAMP-1, lysosome-associated membrane protein-1; PGE~2~, prostaglandin E~2~; IL, interleukin; TNF, tumor necrosis factor; WT-1, Wilms' tumor-1; TAA, tumor-associated antigen; HLA, human leukocyte antigen; IFN, interferon; TriMix mRNA, a mix of 3 mRNA molecules encoding CD70, CD40L and a constitutive active form of toll-like receptor 4 (caTLR4); SKILs, skin infiltrating lymphocytes; MCM, monocyte-conditioned medium.

The use of monocyte-derived vs. plasmacytoid dendritic cells in anti-cancer therapy
-----------------------------------------------------------------------------------

DCs are a heterogeneous population of cells that can originate from both lymphoid and myeloid progenitors, giving rise to distinct DC subsets.[@R36] In humans, DCs are broadly divided into myeloid DCs (myDCs) and plasmacytoid DCs (pDCs). Most vaccination studies today use monocyte-derived DCs (moDCs), which are thought to resemble myDCs, as they can be obtained in vitro at sufficient high numbers starting from CD34^+^ or CD14^+^ progenitor cells. Moreover, these moDCs can be modified with mRNA at high efficiency.[@R37] In contrast, pDCs have not been extensively studied in the context of anti-cancer vaccination. Human pDCs are renowned for their ability to secrete large amounts of type I interferons (IFNs) upon virus encounter. This IFN production aids the maturation of myDCs and activation of T cells (T~H~1 and CTLs) as well as cytolytic natural killer (NK) cells.[@R38]^-^[@R40] Today, it is recognized that pDC-derived type I IFNs also contribute to anti-cancer immunity.[@R41]^,^[@R42] Salio et al.[@R43] demonstrated in vitro that pDCs loaded with melanoma peptide and activated via CD40 ligand (CD40L) were able to activate naive CD8^+^ T cells into melanoma-specific CTLs. In addition, similar to myDCs, pDCs were shown to infiltrate tumors, where they are trapped in an immature state.[@R43]^-^[@R45] Importantly, tumor-residing pDCs can be reverted into pDCs with tumoricidal activity when strong activation stimuli are applied.[@R46]^,^[@R47] These studies highlight the potential of exploiting pDCs similar to the use of myDCs for anti-tumor therapy.

Activation of dendritic cells
-----------------------------

It is generally accepted that the maturation status of the DCs determines the outcome of vaccination.[@R59]^-^[@R64] In 1997, Jonuleit et al.[@R65] proposed an inflammatory cytokine cocktail (CC), consisting of IL-1β, IL-6, TNF-α and PGE~2~ as a potent maturation stimulus. This CC has been extensively used for the maturation of mRNA-modified DCs. However, several drawbacks have been associated to the use of this CC.[@R66]^-^[@R68] Therefore, alternative strategies to mature DCs have been explored. In this regard, the use of Toll-like receptor (TLR) ligands popped up as a strategy to induce maturation of DCs. Activation of DCs via TLRs was shown to have several advantages, including hyperactivation of CTLs and inhibition of the suppressive activity of regulatory T cells (Tregs).[@R62]^,^[@R69]^-^[@R71] In addition, much effort has been put in the development of a one-step-procedure to simultaneously load DCs with tumor antigen mRNA and activate them. Examples hereof are co-electroporation of DCs with tumor antigen mRNA and Ampligen^®^, a dsRNA polyI:C analog[@R72] or TriMix mRNA, a mix of three mRNA molecules encoding CD40L, CD70 and caTLR4.[@R73]^,^[@R74] The combination of CD40L and a constitutive active form of TLR4 (caTLR4) mimics CD40 ligation[@R75] and TLR4 signaling on DCs[@R76] resulting in strong activation of the DCs. The third molecule, CD70 provides a co-stimulatory signal to CD27 expressing T cells resulting in their survival and proliferation.[@R8]^,^[@R73]^,^[@R77] In vitro studies demonstrated that DCs activated with Ampligen^®^ or TriMix mRNA were superior to CC-matured DCs with regard to induction of tumor antigen-specific T cells.[@R72]^-^[@R74] In addition, the first clinical trials with the so-called TriMix-DCs, demonstrated the potential of these DCs for anti-cancer vaccination.[@R20]^,^[@R56]^,^[@R78]^,^[@R79]

Route of vaccine delivery
-------------------------

mRNA engineered DCs need to reach the lymph nodes to induce a potent immune response. Different routes of vaccination such as i.d., s.c., i.n. and i.v. administration have been tested during clinical trials and were well tolerated.[@R26]^,^[@R27]^,^[@R31]^,^[@R48]^-^[@R50]^,^[@R52]^-^[@R54] Two parameters have been considered when evaluating the best route for DC vaccination, i.e. the ability of the administered DCs to migrate to the lymph nodes and their ability to evoke immunological and/or clinical responses. Labeling of DCs with Indium[@R111] and subsequent imaging of their migration has demonstrated that s.c. administered DCs rarely reach regional lymph nodes. Similarly, it was shown that i.v. injection of DCs does not result in their accumulation in lymph nodes[@R80] but in an initial accumulation in the lungs and subsequent redistribution to the liver, spleen and bone marrow.[@R81] In contrast, it has been described that about 4% of ex vivo mRNA-modified DCs can be recovered from lymph nodes when administered i.d.[@R82] Finally, mRNA-transfected DCs were shown to accumulate in draining lymph nodes after intralymphatic administration.[@R83] Importantly, Lesterhuis et al.[@R84] compared i.n. and i.d. administration of ex vivo modified DCs in patients with advanced melanoma, evaluating both migration and induction of tumor antigen-specific immune responses. Despite the higher number of DCs in lymph nodes after i.n. immunization, i.d. vaccination proved to be superior in inducing functional tumor antigen-specific T cells.

Immunization with mRNA: In situ modification of antigen-presenting cells
========================================================================

The direct application of "naked mRNA" for anti-tumor vaccination was instigated after Wolff et al.[@R85] described that injection of mRNA in the muscle of mice resulted in protein expression. It was Conry et al.,[@R86] who first exploited mRNA for anti-cancer therapy, demonstrating induction of protective anti-tumor immunity in mice after intramuscular injection of CEA mRNA. Since then, several papers reported on the induction of anti-tumor immune responses upon "naked mRNA" delivery in a variety of mouse models ([Fig. 1](#F1){ref-type="fig"}; [Table 2](#T2){ref-type="table"}).

![**Figure 1.** From an ex vivo generated DC-based vaccine toward the direct application of naked mRNA for modification of DCs in order to induce in vivo a potent immune response.](hvi-9-265-g1){#F1}

###### **Table 2.** Overview of pre-clinical trials using mRNA for in vivo modification of APCs

  Author                        Year   Route of Administration   Antigen mRNA                                                 Additional Information                                                Outcome
  ----------------------------- ------ ------------------------- ------------------------------------------------------------ --------------------------------------------------------------------- -----------------------------------------------------------
  Conry et al.[@R86]            1995   i.m.                      CEA mRNA                                                     globin UTR stabilized mRNA                                            induction of protective anti-tumor immune response
  Hoerr et al.[@R99]            2000   i.d.                      mRNA encoding defined tumor antigens or an antigen library   globin UTR stabilized mRNA or protamine stabilized mRNA               triggering of antibody and CTL responses
  Granstein et al.[@R100]       2000   i.d.                      total tumor mRNA                                                                                                                   induction of protective anti-tumor immune response
  Carralot et al.[@R101]        2004   i.d.                      β --galactosidase mRNA                                       globin UTR stabilized mRNA, GM-CSF                                    priming of T~H~2 (no GM-CSF) and T~H~1 (GM-CSF) responses
  Scheel et al.[@R102]          2006   i.t.                      β-galactosidase mRNA                                         protamin-stabilized                                                   induction of therapeutic anti-tumor immune response
  Kreiter et al.[@R94]          2010   i.n.                      HA-RNA or SIINFEKL mRNA                                                                                                            induction of therapeutic anti-tumor immune response
  Fotin-Mleczek et al.[@R103]   2011   i.d.                      OVA mRNA or PSMA mRNA                                        2-component vaccine: free and protamin-complexed mRNA                 induction of therapeutic anti-tumor immune response
  Kreiter et al.[@R104]         2011   i.n.                      SIINFEKL mRNA                                                i.p. pre-treatment with Fsm-like tyrosinase kinase 3 ligand (Flt3L)   induction of therapeutic anti-tumor immune response
  Van Lint et al.[@R95]         2012   i.n.                      OVA, Trp2, WT-1 or tyrosinase mRNA                           co-delivery of TriMix mRNA                                            induction of therapeutic anti-tumor immune response

Abbreviations: i.m., intramuscular; i.t., intratumoral; CAT, chloramphenicol acetyltransferase; UTR, untranslated region; HA, hemagglutinin; OVA, ovalbumin; PSMA, prostate-specific membrane antigen.

Dendritic cells instigate antigen-specific immune response after mRNA uptake
----------------------------------------------------------------------------

In the studies described in [Table 2](#T2){ref-type="table"}, the mRNA is often delivered in the dermis or lymph node. Although no direct evidence was provided, it is assumed that i.d. delivery of mRNA results in its uptake by Langerhans' cells and dermal DCs at the injection site for transport to draining lymph node. It is moreover assumed that these DCs transfer their antigenic cargo to lymph node-resident CD8α^+^ DCs when they arrive in the draining lymph nodes.[@R87]^-^[@R91] In this regard Harshyne et al.[@R92] demonstrated that antigens could be transferred between live DCs in vitro. In addition, Kleindienst et al.[@R93] demonstrated that viable vaccinal DCs that migrate to lymph nodes transfer their antigens to lymph node-resident DCs by direct DC-DC contact. Subsequently, these lymph node-resident DCs aid the initiation of antigen-specific T cell responses. Thus cross-presentation of antigenic peptides by endogenous DCs can be seen as a critical event in the effective expansion of functional CTLs. It has been demonstrated that i.n. delivery of mRNA results in the direct modification of lymph node-resident CD11c^+^ cells and the induction of effective antigen-specific T cell responses.[@R94]^,^[@R95] Whether mRNA modified lymph node-resident DCs transfer their antigenic cargo to non-mRNA modified DCs for cross-presentation has thus far not been studied. Nonetheless, it is clear that DCs play a major role in the uptake and translation of mRNA. Therefore, several strategies have been evaluated to enhance the number of DCs before administration of the mRNA, including pre-treatment with granulocyte macrophage-colony stimulating factor (GM-CSF)[@R96]^,^[@R97] and Fms-like tyrosinase kinase 3 (FLT3) ligand.[@R98] These strategies proved to enhance the mRNA-induced immune response.

Activation of dendritic cells
-----------------------------

As with DC vaccination, it is of utmost importance that in situ modified DCs are equipped to stimulate effector T cells. This can only be achieved when these DCs are fully activated. Although it has been described that "naked mRNA" can trigger several pathogen recognition receptors (PRRs) as such providing immune-stimulating capacities,[@R3]^,^[@R94]^,^[@R105]^-^[@R111] much effort is put into the identification of applicable adjuvants to further activate DCs. The study performed by Diken et al.[@R112] highlights that the maturation stimulus and/or timing of its delivery have to be selected carefully as the uptake of mRNA is dependent on macropinocytosis, a function of immature DCs that is lost upon DC maturation. Consequently, co-delivery of classical maturation stimuli, such as lipopolysaccharide (LPS), with tumor antigen mRNA has a negative impact on the bioavailability of the antigen, a parameter which co-determines the induction of antigen-specific T cell responses.[@R95]^,^[@R112] To date two different strategies have been explored to simultaneously load the DCs with tumor antigen mRNA and activate them in vivo. Fotin-Mleczek et al.[@R103] described a two-component system containing free- and protamin-complexed mRNA, providing an antigen source for adaptive immunity together with enhanced triggering of the pathogen recognition receptor, TLR7. This immunization strategy resulted in the induction of a strong anti-tumor immune response and in sustained memory responses, which is important as memory T cells should avoid tumor re-appearance. We have evaluated the use of TriMix mRNA, which was initially described for activation of ex vivo generated DCs, to mature DCs in vivo. We demonstrated that co-delivery of TriMix mRNA did not hamper the uptake and translation of antigen mRNA. Importantly, TriMix mRNA induced a T cell attracting and stimulatory environment, resulting in enhanced induction of antigen-specific T cells. Importantly, mRNA vaccination was shown to be as efficient in induction of CTLs and in therapy as vaccination with mRNA electroporated DCs in several mouse tumor models, stressing the applicability of mRNA as an off-the-shelf therapeutic.[@R95]

Route of vaccine delivery
-------------------------

Similar to immunization with DCs, an important factor affecting the immunological outcome of mRNA-based immunization is the route of vaccine delivery. Thus far, i.d. administration of mRNA is most frequently used, allowing uptake of the mRNA by Langerhans' cells and dermal DCs after which transport to the draining lymph nodes is assumed. More recently, i.n. administration was proposed as the optimal route of mRNA delivery, since lymph nodes are at the center of our immune system harboring a relatively high number of DCs that are in close contact with T cells. When compared with i.d. administration of antigen mRNA, i.n. administration of the mRNA was shown to be superior with regard to induction of antigen-specific T cell responses.[@R94]^,^[@R95]

The first report on intralymphatic vaccination was already published in 1977 by Juillard et al.[@R113] They described the induction of enhanced tumor-specific responses in dogs after intralymphatic administration of the anti-cancer vaccine. Furthermore, it was reported that vaccination by i.n. vaccine delivery required far less antigen when compared with other vaccination routes.[@R114]^,^[@R115] Moreover, biodistribution studies in mice revealed that 100-fold higher antigen doses reached the lymph nodes after direct i.n. injection compared with s.c. injection near the draining lymph node.[@R116] In addition, Maloy et al.[@R117] showed that i.n. immunization with a plasmid DNA vaccine is 100- to 1,000-fold more efficient than immunization via conventional routes. Taken together, the use of i.n. vaccination results in a remarkable reduction of vaccine dose.[@R118] Today, intralymphatic administration is performed in various fields where conventional routes of administration produced insufficient results or where the goal was to maximize the immune response, such as in cancer vaccines. Nowadays, several clinical trials using i.n. immunization are ongoing.[@R58]^,^[@R84]^,^[@R119]^-^[@R123]

Clinical application of vaccination with "naked mRNA"
-----------------------------------------------------

Although the above studies highlight the increasing interest in mRNA as an active, off-the-shelf pharmaceutical ingredient, only a few clinical trials based on the use of "naked mRNA" have been described ([Table 3](#T3){ref-type="table"}). Weide et al.[@R124]^,^[@R125] performed small-scale clinical trials in which total tumor mRNA or stabilized tumor antigen mRNA was delivered i.d. in addition to GM-CSF. These studies described a positive impact on the anti-tumor immune response with even a complete clinical response in one out of seven patients. More recently, Rittig et al.[@R126] showed that i.d. administration of mRNA encoding different tumor antigens together with GM-CSF resulted in both CD4^+^ and CD8^+^ responses against multiple antigens and moreover induced clinical benefit in a number of patients.

###### **Table 3.** Overview of published clinical trials using mRNA for immunization

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                  Year      Type of Cancer                                  Administration Route   Antigen mRNA                                                     Maturation                                                   immunological response                                                                        clinical response
  ----------------------- --------- ----------------------------------------------- ---------------------- ---------------------------------------------------------------- ------------------------------------------------------------ --------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------
  Weide et al.[@R124]     2008      metastatic melanoma                             i.d.                   total tumor mRNA                                                 GM-CSF                                                       antibody and tumor specific T cell responses                                                  no clinical response

  Weide et al.[@R125]     2009      metastatic melanoma                             i.d.                   Melan-A, tyrosinase, gp100, MAGE-A1, MAGE-A3, survivin mRNA      protamin-protected mRNA, GM-CSF either without or with KLH   decrease in Tregs (KLH arm), decrease in MDSCs (non-KLH arm), induction of T cell responses   1/7 CR

  Schmidt et al.[@R127]   2008      renal cell carcinoma                            i.d.                   MUC1, CEA, Her-2/neu, telomerase, survivin, MAGE-A1 mRNA\        GM-CSF                                                       induction of CD4^+^ (3/7) and CD8^+^ T cell responses (8/9)                                   20 µg/TAA: 1/14 PR and 6/14 SD\
                                                                                                           at 20 µg or 50 µg/TAA                                                                                                                                                                                                       50 µg/TAA: 9/16 SD

  Rittig et al.[@R126]    2010      renal cell carcinoma                            i.d.                   MUC1, Her-2/neu, telomerase, survivin, MAGE-A1 mRNA              GM-CSF                                                       CD4/CD8 T cell responses against multiple antigens                                            1/30 PR, 15/30 SD, 14/30 PD

  Curevac[@R128]          ongoing   non small cell lung cancer                      i.d.                   mRNA of 5 different TAAs of which 3 are cancer testis antigens   self-adjuvanted full length mRNA (RNActive**®**)             immune response rate of 84%, response against multiple antigens in 2/3 patients               ongoing

  Curevac[@R129]          ongoing   Advanced castration resistant prostate cancer   i.d.                   PSA, PSCA, PSMA, STEAP1 mRNA                                     self-adjuvanted full length mRNA (RNActive**®**)             immune response rate of 79%, in 58% of the patients these are against multiple antigens       prolonged stabilization of PSA levels, one patient had a drop of over 85% in PSA level
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: MDSCs, myeloid-derived suppressor cells; MUC-1, mucin-1; PSCA, prostate stem cell antigen; STEAP1, six transmembrane epithelial antigen of the prostate 1.

Summary
=======

Since decades the main goal of tumor immunologists has been to increase the capacity of the immune system to mediate tumor regression. The identification of on the one hand DCs and on the other hand tumor antigens paved the way for the development of potent immunotherapeutic strategies for cancer. The use of ex vivo mRNA-modified DCs resulted in promising immunological and clinical responses. Therefore, immunotherapy based on this strategy can be seen as a fourth cancer treatment modality in addition to surgery, chemotherapy and radiotherapy. Furthermore i.n. delivery of tumor antigen mRNA in combination with the appropriate adjuvant for instance by co-delivery of mRNA encoding immune modulating molecules such as TriMix mRNA, represents a promising vaccination strategy. Moreover, the use of mRNA and its application as an off-the-shelf vaccine represent an important step in the development of future anti-cancer immunotherapeutic strategies.

Previously published online: [www.landesbioscience.com/journals/vaccines/article/22661](http://www.landesbioscience.com/journals/vaccines/article/22661/)

10/17/12

10/25/12

This work was supported by the Research foundation Flanders (FWO-V), the Agency of Innovation by Science and Technology, the Interuniversity Attraction Poles Program, the "Stichting tegen Kanker" and Belgian State-Belgian Science Policy. KB is funded by the FWO-V.
